Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Non-Current Deffered Revenue: 2024

Historic Non-Current Deffered Revenue for Aclaris Therapeutics (ACRS) over the last 1 years, with Dec 2024 value amounting to $20.0 million.

  • Aclaris Therapeutics' Non-Current Deffered Revenue fell 17.42% to $17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year decrease of 17.42%. This contributed to the annual value of $20.0 million for FY2024, which is N/A change from last year.
  • Per Aclaris Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $20.0 million for FY2024.
  • In the past 5 years, Aclaris Therapeutics' Non-Current Deffered Revenue ranged from a high of $20.0 million in FY2024 and a low of $20.0 million during FY2024.
  • Moreover, its 1-year median value for Non-Current Deffered Revenue was $20.0 million (2024), whereas its average is $20.0 million.